Navigation Links
Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
Date:4/17/2013

t of $25 million, Phase II requires tearing down the small, two-story BioTech Five on Navy Hill Drive, a process that started this week. The building was used by HDL, Inc.'s sales support, client services, and technology teams, and demolition will make way for the remainder of the headquarters. When complete, HDL, Inc.'s offices and laboratories will encompass 283,000 square feet (approximately five football fields) and hold an additional 400 employees. Features of the headquarters include a rooftop park and green space, a 24/7 gym for employees, and the building's atrium will eventually contain spiral slides connecting the sixth, fifth, and fourth floors. The real estate is valued at roughly $80 million, and with equipment costs HDL, Inc.'s total investment in the biotech park will reach more than $100 million.

Robert T. Skunda , President and CEO of the Virginia BioTechnology Research Park, said Phase II of the Biotech Eight expansion will increase total development at the park to more than 1.25 million square feet of space, representing a capital investment exceeding $560 million. "Few believed that the research park could grow to become such an economic powerhouse when it was first launched 20 years ago. It has put Virginia on the map in biotechnology and the life sciences, and is helping us to compete globally to attract and grow this important sector of our region's economy," he said.

Phase II's financing is provided by Fulton Bank, based in Pennsylvania with a major Virginia presence, as well as Virginia-based banks StellarOne and Xenith Bank.  The Lingerfelt Companies, a Richmond-based developer, has been involved with the project since its inception.

"Since partnering with HDL in 2009, it has been a fast-paced development cycle and we are pleased to assist HDL in its expansi
'/>"/>

SOURCE HDL, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
10. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
(Date:8/18/2014)... Toronto, Canada (PRWEB) August 18, 2014 ... land of opportunity for the clinical research industry. ... clinical trials due to its aging population; a ... in chronic diseases; a densely populated pool of ... enrolment. , Notwithstanding these positive points, China also ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , The ... , , WASHINGTON, Sept. 16 The Foundation ... national animal research education campaign. Since 2004, public support for humane ... points. The ResearchSaves campaign is designed to counter this drop in ...
... , NEW HAVEN, Conn., Sept. 16 Rib-X ... commercialization of novel drugs for the treatment of multi-antibiotic resistant ... the Company,s Board of Directors, succeeding Joseph Amprey, MD, Ph.D. ... of MedImmune, Chief Executive Officer of AstraZeneca North America, and ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3Biomedical Research Organization Launches Groundbreaking National TV Campaign 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... Scientists at the Houston Methodist Research Institute have figured ... using a pipette -- a common laboratory tool that,s ... preliminary test results in a recent issue of the ... "Studying single cells and their unique functions has become ... faculty member Lidong Qin, Ph.D., the project,s principal investigator. ...
(Date:8/19/2014)... awarded a nearly $40,000 grant from the National Center ... the National Park Service (NPS) and U.S. Department of ... of the energy efficiency and cost effectiveness of radiant ... , Radiant barriers are reflective thermal insulations commonly fitted ... reducing the amount of heat emitted in the direction ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... the release of GeneLinker(TM) Gold and Platinum ... and Proteomics Analysis,Software products.,"The new releases are ... data, a high priority for many of ... Protein Biomarker Package into the,latest versions of ...
... will be brought to the marketplace, giving laboratories ... Technology Transfer GmbH (EMBLEM), the commercial entity of ... that it has signed a licensing deal with ... technology called SPIM (Selective Plane Illumination Microscopy). , ...
... There's a,paradigm in life science and drug development : ... occasions I've,seen very promising drugs candidates or related research ... it, even if millions would have,been saved worldwide. The ... drug candidate that affect a "profitable" disease in addition ...
Cached Biology News:Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
... system, 220-240 V, is used for ... The system includes the BioLogic LP ... MV-6 injection valve, proportioning valve or ... and fittings kit, column and conductivity ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: